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Abstract
Investigating genetic architecture of complex traits in ancestrally diverse populations is
imperative to understand the etiology of disease. However, the current paucity of genetic
research in people of African and Latin American ancestry, Hispanic and indigenous peo-
ples in the United States is likely to exacerbate existing health disparities for many common
diseases. The Population Architecture using Genomics and Epidemiology, Phase II (PAGE
II), Study was initiated in 2013 by the National Human Genome Research Institute to expand
our understanding of complex trait loci in ethnically diverse and well characterized study
populations. To meet this goal, the Multi-Ethnic Genotyping Array (MEGA) was designed to
substantially improve fine-mapping and functional discovery by increasing variant coverage
across multiple ethnicities at known loci for metabolic, cardiovascular, renal, inflammatory,
anthropometric, and a variety of lifestyle traits. Studying the frequency distribution of clini-
cally relevant mutations, putative risk alleles, and known functional variants across multiple
populations will provide important insight into the genetic architecture of complex diseases
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and facilitate the discovery of novel, sometimes population-specific, disease associations.
DNA samples from 51,650 self-identified African ancestry (17,328), Hispanic/Latino
(22,379), Asian/Pacific Islander (8,640), and American Indian (653) and an additional 2,650
participants of either South Asian or European ancestry, and other reference panels have
been genotyped on MEGA by PAGE II. MEGA was designed as a new resource for studying
ancestrally diverse populations. Here, we describe the methodology for selecting trait-spe-
cific content for use in multi-ethnic populations and how enriching MEGA for this content may
contribute to deeper biological understanding of the genetic etiology of complex disease.
Introduction
Over the last decade genetic research has made marked advances in cataloging variants associ-
ated with complex traits and human diseases, which in turn has shed new light on etiological
processes. Initial GWAS prioritized genetically homogeneous populations to help prevent spu-
rious findings that could result from population stratification. As such, initial genotyping plat-
forms were intended to capture common genetic variation in populations of European
descent, and later designed to enable efficient imputation of variant reference panels derived
from very large sets of European-descent controls [1]. The sparsity of genetic research in
American minority populations has led to insufficient sample sizes and inadequate genomic
tools for diverse populations. Limited understanding of the genetic heterogeneity in disease
loci across populations could greatly limit variant discovery efforts and exacerbate existing
health disparities in many complex diseases [2]. For example, development of genetic risk
models based on European-descent genetic architecture may, in some cases, have reduced pre-
dictive accuracy in populations with greater genetic diversity and less linkage disequilibrium
(LD) among variants such as African-descent populations [3]. Furthermore, in conjunction
with decreases in genotyping cost, enriching arrays for functional variation and inclusion of
more variants in known GWAS regions can be used as an advantageous research tool. By
leveraging differences in genetic architecture across ancestral populations, transethnic studies
can be used to hone in on likely causal variants in known disease or trait loci. This insight can
enable rich inferences about the underlying biology of complex diseases and may improve risk
modeling across diverse populations.
The Population Architecture using Genomics and Epidemiology (PAGE) consortium
(http://www.pagestudy.org) was initiated in 2008 by the National Human Genome Research
Institute (NHGRI) to investigate the epidemiologic architecture of well-replicated genetic vari-
ants associated with complex diseases in several large, ethnically diverse population-based
studies [4]. The PAGE II consortium, cofounded by the NHGRI and the National Institute for
Minority Health and Health Disparities, consists of four large, ongoing population-based stud-
ies/consortia. Three of these studies were members of the initial PAGE collaboration: the
Women’s Health Initiative (WHI, http://www.whi.org) [5]; the Multiethnic Cohort (MEC;
http://www.uhcancercenter.org/research/the-multiethnic-cohort-study-mec) [6]; a subset of
the studies comprising the consortium Causal Variants Across the Life Course (CALiCo)—
Atherosclerosis Risk in Communities (ARIC, http://www.cscc.unc.edu.offcampus.lib.
washington.edu/aric/) [7], Coronary Artery Risk Development in Young Adults (CARDIA;
http://www.cardia.dopm.uab.edu/) [8], and the Hispanic Community Health Study/Study of
Latinos (HCHS/SOL, http://www.cscc.unc.edu.offcampus.lib.washington.edu/hchs/) [9]. The
fourth PAGE II study is the Charles Bronfman Institute for Personalized Medicine at the
Icahn School of Medicine at Mount Sinai (ISMMS), which curates an electronic health record
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which comprises the Atherosclerosis Risk in
Communities (ARIC) Study, the Coronary Artery
Risk Development in Young Adults (CARDIA)
Study, the Cardiovascular Health Study (CHS), the
Hispanic Community Health Study/Study of Latinos
(HCHS/SOL), and the Strong Heart Study (SHS). A
complete list of members of the PAGE consortium
can be found at [http://www.pagestudy.org]. PAGE
II is funded by the National Human Genome
Research Institute (NHGRI) and is supported by
National Institutes of Health grants U01HG004803
(CALiCo), U01HG004802 (MEC), U01HG004790
(WHI), and U01HG004801 (Coordinating Center).
Characterization of epidemiological architecture in
the Multiethnic Cohort Study is funded through the
NHGRI PAGE II program (grant U01HG004802).
The Multiethnic Cohort Study is funded by the
National Cancer Institute (grants R37CA54281,
R01 CA63, P01CA33619, U01CA136792, and
U01CA98758). Funding for the study of the
epidemiology of putative genetic variants in the
WHI is provided through the NHGRI PAGE
program (grant U01HG004790). The WHI is
funded by the National Heart, Lung, and Blood
Institute (NHLBI) and the US Department of Health
and Human Services through contracts
N01WH22110, 24152, 32100-2, 32105-6, 32108-
9, 32111-13, 32115, 32118-32119, 32122, 42107-
26, 42129-32, and 44221. (The authors thank the
WHI investigators and staff for their dedication). A
full listing of WHI investigators can be found at
[http://www.whiscience.org/publications/WHI_
investigators_shortlist.pdf]. Funding for the CALiCo
consortium was provided through the NHGRI
PAGE program (grant U01HG004803). The ARIC
Study is carried out as a collaborative study
supported by NHLBI contracts N01-HC-55015,
N01-HC-55016, N01-HC-55018, N01-HC-55019,
N01-HC-55020, N01-HC-55021, and N01-HC-
55022. The CARDIA Study is supported by the
following NHLBI contracts: N01-HC-95095, N01-
HC-48047, N01-HC-48048, N01-HC-48049, N01-
HC-48050, N01-HC-45134, N01-HC-05187, and
N01-HC-45205. The Cardiovascular Health Study is
supported by contracts N01-HC-85079 through
N01-HC-85086, N01-HC-35129, N01-HC-15103,
N01 HC-55222, N01-HC-75150, and N01-HC-
45133 and grants U01HL080295 and R01
HL087652 from the NHLBI, with an additional
contribution from the National Institute of
Neurological Disorders and Stroke. Genome-wide
association study DNA handling and genotyping in
the Cardiovascular Health Study was supported in
part by National Center for Research Resources
grant M01-RR00425 to the Cedars-Sinai General
Clinical Research Center genotyping core and by
National Institute of Diabetes and Digestive and
(EHR)-linked medical care setting biorepository (BioMeTM, http://icahn.mssm.edu/research/
institutes/ipm/programs/biome-biobank). In total, 51,650 self-reported African American/
African ancestries, Hispanic/Latino, Asian/Pacific Islander, and American Indian participants
have been genotyped on the Multi-Ethnic Global Array (MEGA). In comparison to previous
efforts, the addition of customized content on MEGA was designed to enable deeper func-
tional exploration of known disease-associated regions, particularly for less frequent (1–5%)
and rare (<1%) genetic variation.
The MEGA array was designed predominantly through the collaborative efforts of Illumina,
the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA),
and PAGE II to empower GWAS in diverse ancestry populations. Customized content was
included on the MEGA to improve our understanding of genetic loci associated with complex
human diseases or traits and to evaluate potential genetic heterogeneity across racial/ethnic
groups. Specifically, we selected custom content to: 1) explore the generalization or replication
of previously-reported genotype-phenotype associations at known loci; 2) identify indepen-
dent or population-specific variant associations within known associated regions; 3) leverage
differences in haplotype structure (LD) across populations to hone in on likely causal variants
in known trait-associated regions (‘fine-mapping’); and 4) perform candidate functional SNP
analysis using variants known to be (a) clinically relevant, (b) implicated in candidate path-
ways, or (c) validated as regulatory through laboratory analyses such as allelic reporter assays.
Given that functional variants for the majority of GWAS signals have not been identified,
the design of MEGA will enable researchers to provide new understanding of the biology
underlying known disease associations and improve the generalizability of risk models
across populations. Here, we describe both the custom designed MEGA content and discuss
valuable insights gained through design efforts that may be of interest to the greater research
community.
Methods
MEGA content allocation
MEGA content was partitioned into two major categories: 1) ‘backbone content’ used for
agnostic GWAS and exome analyses in ancestrally diverse populations, and (2) ‘PAGE hand-
curated custom content’ for targeted analyses aimed at discovering causal variants. The ‘back-
bone’ of the array has been described elsewhere [10,11] (https://www.pagestudy.org/index.
php/multi-ethnic-genotyping-array) and is summarized in Table 1. Briefly, the backbone con-
tains highly informative SNPs for GWAS analyses in European and East Asian descent popula-
tions for backwards compatibility with other genotyping arrays. These variants, often referred
to as tag SNPs, are positioned in regions of the genome with high LD and typically represent
common haplotypes in populations of either European or East Asian descent. However, the
vast majority of the MEGA backbone content (83%) empowers GWAS and Exome analyses in
African ancestry and Hispanic/Latino populations. The backbone content also includes the tag
SNP phenotype associations from the NHGRI GWAS catalog, SNPs that are mentioned in
four or more publications (‘SNPs in Publications’ database from the UCSC table browser)[12],
and clinically relevant variants (Table 1).
Overview of custom content selection
The custom content available on MEGA was taken from four primary sources: large-scale
GWAS, thorough literature review, publicly available variant databases (e.g. 1000 Genomes
Phase 3 Project, ClinVar, OMIM, UCSC Table Browser ‘SNPs in Publications’ track), and rec-
ommendations from experts on traits of interest to PAGE II. Along with variant annotation
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tools (e.g. Variant Effect Predictor and ANNOVAR) these resources were used to prioritize
known trait loci and select content that could be used to: 1) replicate or generalize index
GWAS associations, 2) augment GWAS tagging SNPs in priority regions 3) enhance exome
content in priority regions, 4) fine-map GWAS loci, (5) identify functional regulatory variants,
(6) explore penetrance/frequency of clinically reported variants in a population-based cohort,
and (7) identify novel variant loci in suspected candidate pathways.
Prioritizing known GWAS trait loci
Summary statistics for the largest available GWAS were mined to nominate both known and
candidate loci tagging effects for traits related to type 2 diabetes (T2D), inflammation, lipids,
coronary heart disease (CHD), blood pressure, kidney disease, anthropometric measurements,
various lifestyle traits like alcohol consumption, smoking, and reproductive traits. These traits
were prioritized based on the availability of phenotypic data in the samples selected for geno-
typing in PAGE II. For GWAS-based datasets, we queried summary level data for the afore-
mentioned traits, including both published and unpublished datasets. Using the NHGRI
GWAS catalog [13] (available at: http://www.ebi.ac.uk/gwas date of access: March 19, 2014),
we first identified traits directly or indirectly related to prioritized PAGE II traits. In order to
maximize power, associations directly related to our traits were rank ordered and studies with
Table 1. Marker allocation used for design of MEGA.
Abbreviated reference Approximate SNP
allocation
Content description Parameters informing content
Backbone content
Infinium HumanCore
BeadChip
250,000 Included for backwards
compatibility
Highly informative GWAS tag SNPs for EUR or ASN ancestries
African Diaspora
Consortium Power Chip
700,000 Augmented GWAS coverage for
African ancestries
692 individuals sequenced by CAAPA, highly informative for
variants with MAF>2%
Improved cross-population
tagging content
300,000 Augmented GWAS coverage for
diverse ancestries
New tagging strategy developed by PAGE using 1KGP Phase
3 sequencing, highly informative for variants with MAF<2%
Multiethnic exonic content 400,000 Exome markers for diverse
populations
Derived from WGS/WES data from > 36,000 individuals in
diverse ethnic groups, emphasizes loss of function and splice
variants
NHGRI GWAS catalog 11,631 Markers (tag SNPs) from published
GWAS
Includes tag SNPs not reaching genome-wide significance
(p<5x10-8), and SNPs in high LD
SNPs in publications 5,874 SNPs listed in UCSC browser track Mentioned by rsid number in 4 publications
Clinical and
pharmacogenetic
17,000 All clinically relevant SNPs Domain expert opinion and those annotated as deleterious
PAGE Hand Curated Custom Content
Validated regulatory SNPs 2,500 Regulatory variants with in vitro
differential function in the literature
Differential EMSA, most with differential luciferase or
equivalent
Enhanced GWAS 20,000 Improved tag SNP coverage for
candidate genes/regions
Minimum r2 of 0.8 rather than mean r2 of 0.6 used for backbone
Enhanced Exome 16,000 Improved exonic coverage for
candidate genes/regions
All available exonic variants
Fine-mapping 16,000 Fine-mapping coverage for GWAS
catalog reports
All SNPs tagged at r2 > 0.6 in reference population from primary
GWAS report
OMIM/Clinvar a Overlaps backbone
content
Clinically relevant SNPs related to
traits of interest
E.g. hyperlipidemia (LPL, LDLR, etc.), BMI (MC4R, etc.)
a OMIM/Clinvar datasets were subsequently added as back-bone content when variant classified as deleterious. Additional ‘likely deleterious’ variants were
added if directly related to traits of interest; MAF = Minor Allele Frequency; 1KGP = 1000 Genomes Project; AFR, AMR, ASN, EUR = 1000 Genomes
Project Phase 3 super populations; WGS/WES = whole genome sequencing/whole exome sequencing; EMSA = electrophoretic mobility shift assay
doi:10.1371/journal.pone.0167758.t001
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National Institutes of Health; OMIM, Online; PCR,
Polymerase Chain Reaction; PAGE II, Population
Architecture using Genetics and Epidemiology
Phase II; SAS, South Asian 1000 Genomes Phase
3 super population; SNP, Single Nucleotide
Polymorphism; T2D, Type 2 Diabetes; Tag SNP,
tagging SNP (also referred to as index SNP) utilized
in GWAS; UCSC, University of California Southern
California; UTR, Untranslated Region; WHI,
Women’s Health Initiative.
smaller discovery populations were prioritized to give greater weight to variants with larger
effects. The top 500 ranked associations were selected for locus refinement. For GWAS aug-
mentation (described below), loci were defined as 100kb upstream and downstream (200kb
total) of the index SNP position in the GRCh37/hg19 build.
Variant annotation
All variants selected for inclusion were annotated using the ‘Snp 142 common’ and ‘All SNPs
(142)’ datasets in the UCSC Table Browser. We also used the bedtools utility ‘intersect’ to iden-
tify overlap between variant lists, such as the list of functional SNPs, and PAGE II trait loci of
interest (GWAS loci and prioritized trait group genes). Coding variants were annotated using
multiple annotation methods (ANNOVAR, Variant Effect Predictor, Variant Annotation Inte-
grator, and Variant Annotator-GATK) and the most likely deleterious annotation was assigned.
Augmentation of GWAS tagging SNPs in priority loci
MEGA contains a GWAS scaffold designed for enhanced imputation accuracy across multiple
populations [11]. In addition to providing an essential tool that can be used for more compre-
hensive genetic studies in diverse populations (for both less frequent and common variants),
we aimed to enhance genome-wide coverage in regions previously implicated for PAGE II
traits of interest. Our methodology to develop the improved multi-ethnic tag SNP selection for
MEGA [14] was extended to the custom content regions. Assigning the rest of MEGA as fixed
content, tags were selected to enhance coverage in the regions of interest across all 6 continen-
tal populations found in 1000 Genomes Project Phase 3 data: Admixed African-Descent
(AAC), African (AFR), Americas (AMR), East Asian (ASN), European (EUR), and South
Asian (SAS). Tags were selected using a minimum MAF of 1% and a minimum LD r2 of 0.2.
GWAS loci were defined as 100kb upstream and downstream (200kb total) of the index SNP
position in the GRCh37/hg19 build.
Augmentation exome SNPs in priority loci
In the prioritized genes of interest, we lowered the MAF threshold compared to the rest of the
MEGA backbone to allow inclusion of doubleton or singleton observations. Synonymous vari-
ants were also included in these genes because evidence suggests these can also be functional,
whether as miRNA targets or as exonic splice enhancers/silencers [15–23].
Fine-mapping SNPs in priority loci
For our list of GWAS catalog prioritized trait associations (see details above), we defined the
variants at a locus as the index variant and all correlated SNPs with an r20.6 within 200 Kb.
LD calculations were derived from 1000 Genomes Phase 3 Project SNP coverage (ftp://ftp.
1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/ALL.chr10.phase3_shapeit2_mvncall_
integrated_v2.20130502.genotypes.vcf.gz). Using vcftools v0.1.12a, pairwise LD was calculated
in the relevant 1000 Genomes Project super populations: EUR was used when the index dis-
covery sample included European-descent populations, and ASN was used for discovery popu-
lations of East or South Asian-descent [24]. Tagged SNPs were excluded if they were triallelic
or they had a MAF < 1%.
Identification of functional regulatory variants
In order to perform functionally informed analyses, we included variants that regulate gene
expression as determined through laboratory analyses such as luciferase reporter assays and
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electromobility shift assays (EMSA). To achieve this, we mined both PubMed and Google
Scholar to extract terms in the abstract and text. Our search included the following terms:
“reporter”, “EMSA”, “luciferase”, “catalase”, “GFP”, or “Chromatin Immunoprecipitation.”
One of the largest challenges in this endeavor was identifying which variant was being
reported. There are many different ways to reference a polymorphism, and prior to GWAS,
the variant was almost never referred to by the now-standardized dbSNP rsID number. For in-
stance, pharmacogenetic variants were often reported using a ‘gene asterisk variant’ notation (eg.
CYP2A69) and many other studies reported variants relative to Transcription Start Sites (TSS;
eg. -1031T/C). Furthermore, upstream and downstream references were arbitrarily defined as ‘+’
or ‘-‘.When a sequence was provided we used the “BLAT” tool from UCSC Genome Browser
(http://genome.ucsc.edu/) to identify the correct variant. If no sequence was available but prim-
ers were provided we used the UCSC ‘In-Silico PCR’ tool. Occasionally we were able to find link-
age between the rsID number and the alias in a different article using the ‘SNPs in Pubs’ track.
Articles were further reviewed in an effort to verify that reports of ‘differential allelic expression’
were statistically significant after Bonferroni correction when multiple variants were analyzed.
Results
Augmented GWAS loci and trait related genes
After hand curation of the GWAS catalog tag SNPs directly related to the following traits were
selected: T2D (n = 95), inflammation (n = 527), lipids (n = 379), CHD (n = 280), blood pres-
sure (n = 121), kidney disease (n = 92), anthropometric (n = 644), and lifestyle or menstrual
related traits (n = 107). In total, we rank ordered the list of 4,453 unique locus tag SNPs. The
top 500 ranked associations were selected for locus refinement.
In addition to prioritizing these known and well-powered GWAS loci, 166 genes (Table 2)
were prioritized across these eight trait groups based on thorough literature review, clinical
relevance, and recommendation by experts with proficient genetic knowledge and clinical
knowledge on the priority PAGE II traits. Gene coordinates were defined using the UCSC
Table Browser UCSC Genes (GRCh37/hg19) and taking the union of the reported transcripts.
These 166 gene coordinates were used to augment exome content and select GWAS tag SNPs.
Custom content on MEGA
After applying Illumina design filters to select SNPs that are less likely to fail and removing
overlap between categories a total of 48,091 SNPs were included as custom design for MEGA
(Table 3). In comparison to the GWAS backbone we observed that the customized content
was enriched for rarer variation (Fig 1).
Replication or generalization of index associations
All published genome-wide significant variants related to PAGE II traits of interest were spe-
cifically chosen for inclusion on MEGA. In addition, we included 302 unpublished variants
reaching genome-wide significance in PAGE I studies or in the large consortia―GIANT
(https://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium), and
MAGIC (http://www.magicinvestigators.org/). These loci were reported in European, His-
panic, Asian, or African American populations. In addition, we performed a literature search
in PubMed for targeted genotyping arrays (‘MetaboChip’, ‘ExomeChip’, ‘OncoArray’, and
‘ImmunoChip’) to identify additional associations that may not have been included in the
NHGRI GWAS catalog. We identified an additional 102 variants significantly associated with
one or more PAGE II prioritized traits.
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Augmented GWAS Tagging SNPs in Priority Regions
A total of 28,465 tag SNPs were selected for augmenting coverage over 84.7 Mb containing 157
priority genes (+/- 50kb flanking regions) and 459 highly ranked GWAS loci (+/- 100kb flank-
ing regions). Of those tag SNPs 25,388 made it onto MEGA after QC (S1 Table). In addition to
Table 3. Custom Content Variants Before and After Design.
Source Before Design
Filter
Content Included On
MEGA
SNPs in more than 4 publications 2,894 2,849
GWAS catalog 4,915 4,496
Gene-Environment Interaction 139 122
Pharmacogenetic 1,616 1,495
Unpublished GWAS 327 215
Enriched GWAS (S1 Table) 28,465 25,388
Enriched Exome (S2 Table) 14,001 5,733
Fine-map (S3 Table) 15,049 11,974
Regulatory SNPs (literature review of differential allelic
assay experiments) (S4 Table)
2,617 1,577
Priority SNPs Requested by Trait group (S5 Table) 3,752 2,278
Targeted genotyping array results (S6 Table) 129 119
doi:10.1371/journal.pone.0167758.t003
Table 2. List of Prioritized Genes by Trait.
Traits Genes of Interest
Obesity/ Anthropometry ACVR2B, CAPN3, FTO, GALNT10, IRX3, KSR2, LEPR*, MRAP2, MTCH2,
NEGR1, PCSK1*, PRKCH, RMST, RPGRIP1L, SEC16B, SIM1, TFAP2B,
TUB,
Kidney disease/ Blood
pressure
ABCG2, APOL1, ARID5B, AS3MT, C1GALT1, C1GALT1C1, CUBN,
GALNT2, GALNT14, HECW1, HOXA3, KCNK3, MYH9, PDZK1, RAPH1,
SGK1, SLC17A1, SLC2A9, SLC22A11, SLC22A12, SLC16A9,
ST6GALNAC2, TMEM171, UMOD
Coronary Heart Disease CAV1/CAV2, KCNH2, NKX2-NKX5, MEIS1, PRKCA, SCN5A/SCN10A,
SOX5, TBX5/TBX3, WNT11, ZFPM2/FOG2
Inflammation ABO, ADAMTS13, AGER, APOE, CRP, CD36*, DARC, EPO, F7, FGB,
FGG, G6PD, HNF1A, HNF4A, HBB, HFE, ITGB3, IL6R, JAK2, LCT, LEPR*,
MPL, SH2B3, SORT1, TRF2, TUBB1, ZFP36L1
Alcohol use GABRA2, OPRM1, KCNJ6, CHRM2, TAS2R38, TAS2R16, ADH1B,
ADH1C, AUTS2, ALDH2
Smoking CHRNA5, CHRNB4, CHRNB3, CHRNA6, CHRNA3, CHRNA4, GPR51,
UGT2B10
Age at Menarche ZNF483, FLRT2, CYP19A1, PIK3R1*, DLGAP2, AKT3, CENPW, LIN28B,
LRP1B, RORA
Age at Menopause ASH2L, HELQ, INHBA, NFAT5, NLRP11, OLFM2, POLG, PRRC2A,
RHBDL2, TLK1, U1MC1
Lipids AGPAT2, BAAT, CD36*, CPT1A, CPT2, CYP27A1, FABP2, HMGCR, LIPA,
LMF1, NPC1L1, PCSK1*, PCSK7, PCSK9, PNPLA2, PPARA, PPARG,
SLCO1B1, TM6SF2
Type 2 Diabetes ABO, ACP2, APOL2, ANKH, ARAP1, COBLL1, CTNNAL1, CYB5A, DNLZ,
DYRK1B, FAM206A, G6PC2, GLP1R, GPSM1, GRB14, HMGA1, IKBAP,
KANK1, LIMK2, MADD, NUDT3, OR2AK2, PAM, PIK3R1*, RNF10, RREB1,
SLC2A2, SLC30A8, SGSM2, SHBG, SSR1, TBC1D30, TET2
* Genes present in multiple trait groups
doi:10.1371/journal.pone.0167758.t002
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Fig 1. Enrichment of rarer variation in custom content. Comparison of minor allele frequency distribution between the MEGA GWAS backbone
and the custom content stratified by race. Allele frequencies were calculated in PAGE II study populations.
doi:10.1371/journal.pone.0167758.g001
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the background GWAS scaffold, there were on average 41 tag SNPs per prioritized genes and
GWAS top hit. (S7 and S8 Tables)
Imputation accuracy was assessed through a leave-one-out internal validation approach,
using the 1000 Genomes Project phase 3 data. Pearson’s correlation was estimated between the
imputed dosages and the genotypes found in the original data. A scaffold of all MEGA sites
was compared to MEGA excluding all custom content, including enhanced exome content,
and SNPs added to fine-map previously implicated GWAS loci. An increase in performance
was seen across all populations (Fig 2). The largest increase in imputation accuracy was found
in low frequency loci, with a MAF below 5%. Imputation accuracy improvement was most
notable for AA populations, with an accuracy increase of 3.02% points in AFR for loci with
MAF between 0.5% and 1% (Table 4).
Enhanced exome in priority regions
In the 166 genes of interest we selected 14,000 additional variants for inclusion on MEGA. In
total 5,733 additional exome content SNPs were included on MEGA after exclusion of those
with poor quality, mapping issues, or other synthesis issues. Using multiple annotation methods
(ANNOVAR, Variant Effect Predictor, Variant Annotation Integrator, and Variant Annotator-
GATK) and taking the most likely deleterious annotation assigned to each variant, we obtained:
Fig 2. Improved imputation accuracy found with custom content sites in regions of interest. Solid lines denote the imputation accuracy of
MEGA including the custom content, while dashed lines indicate the performance of MEGA without the custom content. Admixed populations are
on the left, with continental populations found on the right.
doi:10.1371/journal.pone.0167758.g002
Table 4. Enhanced Imputation Accuracy with Custom Content Addition.
Population Minor Allele Frequency Threshold
0.5–1% 1–5% >5%
AAC 2.75% 2.63% 0.84%
AFR 3.02% 2.79% 0.98%
ASN 1.79% 1.89% 0.54%
AMR 2.20% 2.27% 0.43%
SAS 2.65% 2.38% 0.52%
EUR 2.48% 2.75% 0.43%
doi:10.1371/journal.pone.0167758.t004
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36 stop gained, 2 stop lost, 97 frameshift, 49 in frame variants, 12 splicing variants, 1,144 3’ UTR,
810 5’ UTR, 1,725 non-synonymous and, 3,144 synonymous variants. The median allele fre-
quency of these variants across populations was 0.05% (interquartile range = 0.04%-0.1%).
Fine-mapping GWAS loci
For our list of GWAS catalog prioritized trait associations, we defined the variants at a locus as
the index variant and all correlated SNPs with an r20.6 within 200 Kb. This resulted in
15,049 variants representing 459 prioritized loci directly related to our traits of interest (S3
Table). We included up to 338 variants per fine-mapped locus, with an average of 33 (SD = 38)
variants. After applying the Illumina design score filter of>0.5, 12,199 SNPs in 451 indepen-
dent loci remained. The average number of variants per locus was similar with a mean of 27
(SD = 32) variants. The average minor allele frequency was 39% across the 12,199 variants.
Identification of Functional Regulatory Variants
In total, our literature search identified 2,610 variants showing significant differential allelic
gene expression. We found that of the variants tested in an allelic assay that were also described
as having function only 260 (10%) were strongly tagged (r2>0.6) by a GWAS index SNP.
Although these variants could be the underlying functional variant for the association, it
should be noted that they are not necessarily the variant underlying the association and in
some circumstances there may be multiple or ethnic specific variants in a known locus. How-
ever, this supports the assertion that for the vast majority of associated loci the underlying
causal variants have not been fine-mapped. Furthermore, while many of the GWAS loci identi-
fied to date are positioned in intergenic regions, until recently most of the regulatory variant
follow-up has been conducted in promoters where the target gene is known (Fig 3).
Fig 3. The functional hypothesis tested (‘Hypothesized Function”) by year for 2,610 variants reported in a functional allelic assay found through
literature review.
doi:10.1371/journal.pone.0167758.g003
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Selection of medically important variants
Putative risk variants identified by exome sequencing of familial and population based sam-
ples, as well as those derived from literature review for highly penetrant diseases related to our
more common traits of interest, were also included on the array. To accomplish this, we per-
formed a systematic literature and database search for all mutations known to cause medical
traits like hyper/hypolipidemia, hypercholesterolemia, dyslipidemia, lipodystrophy, arterio-
sclerotic heart disease, chronic kidney disease, extreme obesity, maturity onset diabetes of the
young (MODY), long QT syndrome, Brugada syndrome, alcohol and nicotine dependence or
sensitivity, systemic lupus erythematosus, and airway hyper-reactivity. Using ClinVar [25],
OMIM [26] and NextBio (http://www.illumina.com/informatics/research/biological-data-
interpretation/nextbio.html) we obtained 2,655 candidate variants.
Identification of variants in candidate pathways
We selected 1,546 variants for candidate pathway analyses based on their involvement with
pharmacokinetics or pharmacology (for example: absorption, distribution, metabolism and
excretion-ADME; or drug-metabolizing enzymes and transporters-DMET) from publicly
available resources (www.pharmaadme.org, http://www.snpedia.com/index.php/Pharma_
DMET, http://www.drugbank.ca/genobrowse/snp-adr).
Discussion
The design of MEGA enables the most comprehensive examination of genetic architecture
across ancestrally diverse populations to date, and thus provides a key tool for discovering
important insights for many complex diseases and traits. In this manuscript, we have
outlined the custom content that was hand-curated by PAGE II in order to improve our
understanding of genetic loci associated with complex human diseases or traits and to eval-
uate potential genetic heterogeneity across racial/ethnic groups. This high-value content
includes: (1) variants relevant to common, complex phenotypes of interest to PAGE II; (2)
candidate functional variants in non-coding regions curated from the literature; (3) fine-
mapping content selected to refine established GWAS signals reported in the GWAS cata-
log; and (4) augmented coverage in candidate regions containing either genes of interest or
relevant GWAS associations.
The extensive effort taken to utilize existing knowledge on the genetic etiology of complex
traits has enabled PAGE II to enrich the genotyping content in those regions most likely to
influence our traits of interest across all populations. Ultimately, the usage of MEGA in this
large multi-ethnic study will provide necessary insight into the genetics of complex diseases
and help ensure that the benefits gained from genetic research are equitably distributed across
diverse populations. For instance, development of genetic risk models based on European
genetic architecture alone may in some cases reduce predictive accuracy in other ethnicities
[27–30]. Additionally, by leveraging differences in genetic architecture across ancestral popu-
lations, transethnic studies can be used to hone in on likely functional variants in known dis-
ease or trait loci. Genetic risk models built on tagging variation that is informative across
populations will ensure that all ethnic/racial groups are benefitting from the knowledge gained
from the public investment in genetic research. Furthermore, by enabling functional insight in
genetic risk loci, inferences on the underlying biology of complex diseases can better inform
the development of treatment therapies.
The customized content selection sought to identify a set of truly functional variants from
thorough literature review. MEGA includes variants that mark associations with gene expres-
sion (6689 genomic loci regulating mRNA expression-eQTLS) and those predicted in silico to
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have regulatory potential (RegulomeDB); these variants represent a gold standard for estab-
lishing regulatory function. The inclusion of variants that have been shown to influence gene
expression in the laboratory will assist in fine-mapping associated loci and enable candidate
variant associations. In our hand-curation process, we found that although more than a thou-
sand allelic functional assays have been published, many were from before the time of GWAS
and most were not conducted as a follow-up to a GWAS study. Furthermore, most of the asso-
ciated loci to date did not overlap with a variant shown to be functional. Similarly, the vast
majority of variants shown to be functional through laboratory assays have been positioned in
the promoter, although most associations to date have been positioned in enhancer regions.
As such, for the vast majority of associated loci there remains a significant amount of work to
be done in identifying the underlying causal variant(s) and target genes. As efforts were taken
to include variants predicted to have regulatory function or a deleterious effect in the coding
region, we believe the inclusion of tagging variants that are most informative across popula-
tions will enable better prioritization of likely causal variant associations and thus streamline
laboratory follow-up.
To facilitate rapid dissemination of results and methods, as well as promote new collabora-
tions with other studies, PAGE II investigators have created a link within the study website
(http://pagestudy.org/) to report usage of MEGA.
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